Lonza Group Stock Value
Lonza Group Company Info
EPS Growth 5Y
0,15%
Market Cap
CHF34,71 B
Long-Term Debt
CHF3,88 B
Annual earnings
N/A
Dividend
CHF4,97
Dividend Yield
1,01%
Founded
1897
Industry
Country
Website
ISIN Number
Website
Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.
CHF670,00
36.23%
Last Update: 03/27/2026
Analysts: 23
Highest Price Target CHF815,00
Average Price Target CHF670,00
Lowest Price Target CHF550,00
In the last five quarters, Lonza Group’s Price Target has risen from CHF532,80 to CHF576,86 - a 8,27% increase. Seventeen analysts predict that Lonza Group’s share price will increase in the coming year, reaching CHF670,00. This would represent an increase of 36,23%.
Top growth stocks in the health care sector (5Y.)
What does Lonza Group do?
Lonza Group AG is a preferred global partner to the pharmaceutical, biotech, and nutrition markets. The company harnesses scientific innovation and manufacturing technology to enable customers to serve patients and consumers effectively. The company is structured across four divisions: Biologics, Small Molecules, Cell & Gene, and Capsules & Health Ingredients.
Business Segments
The company operates through four primary business segments,
Biologics
This division includes mammalian and microb...
Lonza Group Questions and Answers
Which sectors generate sales and which are the top 3 markets?
**Revenue distribution by industry:**
- **Pharma & Biotech:** 75%
- **Specialty Chemicals:** 25%
**TOP 3 Markets:**
- **USA:** 40%
- **Europe:** 30%
- **Asia-Pacific:** 20%
The Lonza Group AG generates the majority of its revenue in the Pharma & Biotech sector, which is attributed to its s...
At which locations are the company’s products manufactured?
**Production sites of Lonza Group AG:**
1. **Visp, Switzerland**
2. **Basel, Switzerland**
3. **Portsmouth, USA**
4. **Slough, United Kingdom**
5. **Singapore**
Lonza Group AG is a globally active company specializing in the production of pharmaceutical and biotechnological products. The main prod...
What strategy does Lonza Group pursue for future growth?
**Strategy for Future Growth:**
1. **Focus on Biopharmaceuticals:** Lonza is heavily investing in the production of biopharmaceuticals to meet the increasing demand in this sector. This includes both expanding existing production capacities and constructing new facilities.
2. **Expansion of Produc...
Which raw materials are imported and from which countries?
**Main raw materials:** Chemicals, biological materials, special polymers
**Countries of origin:** USA, Germany, China, India
Lonza Group AG, a leading company in the life sciences industry, imports a variety of raw materials necessary for the production of pharmaceutical and biotechnological prod...
How strong is the company’s competitive advantage?
**Competitive Advantage:** Strong
The Lonza Group AG possesses a significant competitive advantage based on several factors. Firstly, the company holds a leading position in the field of contract development and manufacturing of pharmaceutical and biotechnological products. This position is support...
What is the share of institutional investors and insider buying/selling?
**Institutional Investor Share:** approx. 70% (estimate for 2025 based on historical data)
**Insider Buys/Sells:** No significant transactions in the last quarter (estimate for 2025)
The institutional investor share at Lonza Group AG traditionally stands at around 70%, indicating the trust of majo...
What percentage market share does Lonza Group have?
**Market share of Lonza Group AG:** Estimated around 10% (2025)
**Main competitors and their market shares:**
1. Thermo Fisher Scientific: around 15%
2. Catalent: around 12%
3. Lonza Group AG: around 10%
4. Samsung Biologics: around 9%
5. Boehringer Ingelheim BioXcellence: around 8%
6. Wuxi Biologi...
Is Lonza Group stock currently a good investment?
**Revenue growth:** 8.9% (2024)
**EBITDA margin:** 28.5% (2024)
**R&D expenses:** 10% of revenue (2024)
The Lonza Group AG recorded a revenue growth of 8.9% in 2024, indicating strong demand for its services in the biotechnology and pharmaceutical manufacturing sector. The EBITDA margin o...
Does Lonza Group pay a dividend – and how reliable is the payout?
**Dividend payment:** No dividend (2025)
The Lonza Group AG has not paid any dividends in recent years. The company has focused on reinvesting its profits into the growth and expansion of its business activities. This strategy is reflected in the strengthening of its market position and the develop...
